The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $6.43

Today's change+0.07 +1.10%
Updated June 30 4:00 PM EDT. Delayed by at least 15 minutes.
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $6.43

Today's change+0.07 +1.10%
Updated June 30 4:00 PM EDT. Delayed by at least 15 minutes.

PDL BioPharma Inc up (U.S.)$0.07

PDL BioPharma Inc closed up Tuesday by (U.S.)$0.07 or 1.10% to (U.S.)$6.43. Over the last five days, shares have lost 3.31% and sit 4.05% above their 52-week low. This security has underperformed the S&P 500 by 38.82% during the last year.

Key company metrics

  • Open(U.S.) $6.39
  • Previous close(U.S.) $6.36
  • High(U.S.) $6.48
  • Low(U.S.) $6.36
  • Bid / Ask(U.S.) $6.27 / (U.S.) $6.55
  • YTD % change-16.60%
  • Volume1,916,397
  • Average volume (10-day)2,262,127
  • Average volume (1-month)2,405,695
  • Average volume (3-month)3,041,550
  • 52-week range(U.S.) $6.18 to (U.S.) $10.26
  • Beta0.65
  • Trailing P/E3.36×
  • P/E 1 year forward3.02×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.60
  • Dividend yield9.33%
  • Trailing EPS(U.S.) $1.91
Updated June 30 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+56.19%

Based on its net profit margin of 56.19%, PDL BioPharma Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.44%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue150117165163
Total other revenue--------
Total revenue150117165163
Gross profit--------
Total cost of revenue--------
Total operating expense81867
Selling / general / administrative81867
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0000
Other operating expenses, total--------
Operating income14299159156
Interest income (expense), net non-operating-9-9-9-10
Gain (loss) on sale of assets--------
Other--------
Income before tax13490150146
Income after tax845510292
Income tax, total49354754
Net income845510292
Total adjustments to net income--------
Net income before extra. items845510292
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items845510292
Inc. avail. to common incl. extra. items845510292
Diluted net income855510292
Dilution adjustment1000
Diluted weighted average shares170197167177
Diluted EPS excluding extraordinary itemsvalue per share0.500.280.610.52
Dividends per sharevalue per share0.150.150.150.15
Diluted normalized EPSvalue per share0.500.280.610.52